KTR7 Antibody

What is TLR7 and why is it important in immunological research?

TLR7 is a 120 kDa type I transmembrane glycoprotein belonging to the Toll-like receptor family. Human TLR7 is synthesized as a 1049 amino acid precursor containing a 26 aa signal sequence, an 803 aa extracellular domain, a 21 aa transmembrane sequence, and a 189 aa cytoplasmic domain . TLR7 is critical in immunological research because it recognizes single-stranded RNA and participates in innate immune responses to microbial agents . Additionally, TLR7 signaling has been shown to accelerate germinal center formation, promote affinity/avidity maturation of virus-like particle (VLP)-specific IgG, and drive isotype switching to IgG2b/2c . Its role in both normal immune function and autoimmune pathology makes it a significant research target.

How does TLR7 differ from other toll-like receptors in function and distribution?

TLR7 has specialized functions in recognizing single-stranded RNA molecules, distinguishing it from other TLRs that recognize different pathogen-associated molecular patterns. It is primarily detected in brain, placenta, spleen, stomach, small intestine, lung, and in plasmacytoid pre-dendritic cells . Unlike some other TLRs, TLR7 plays a particularly important role in B cell biology, where it shapes and maintains antibody diversity through B cell intrinsic mechanisms . This was demonstrated through chimeric mice studies where mice lacking TLR7 expression exclusively in B cells showed compromised IgG responses .

What are the key considerations when selecting a TLR7 antibody for research?

When selecting a TLR7 antibody, researchers should consider:

• Specificity: Ensure the antibody specifically recognizes TLR7 without cross-reactivity to other TLRs

• Application suitability: Verify the antibody has been validated for your intended application (flow cytometry, immunohistochemistry, etc.)

• Clone information: Monoclonal antibodies like clone 533707 have been validated for specific applications

• Subcellular localization: Consider whether you need antibodies that can detect intracellular vs. surface TLR7

• Species reactivity: Confirm the antibody recognizes TLR7 in your species of interest (human TLR7 is 81% identical to mouse TLR7)

• Validation data: Review scientific data provided by manufacturers showing detection in relevant cell lines

How can TLR7 antibodies be optimally used in flow cytometry experiments?

For optimal flow cytometry with TLR7 antibodies:

• Cell preparation: Use proper fixation and permeabilization buffers as TLR7 is primarily intracellular. Flow Cytometry Fixation Buffer followed by Permeabilization/Wash Buffer I has been validated for this purpose .

• Antibody dilution: Determine optimal antibody concentration through titration. Standard protocols suggest 20 μg/mL for coating , but optimal dilutions should be determined by each laboratory .

• Controls: Always include appropriate isotype controls (e.g., MAB003 has been used as isotype control for TLR7 antibody MAB5875) .

• Secondary antibody selection: For indirect detection, Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody has been successfully used .

• Protocol example: For intracellular staining, follow validated protocols such as "Staining Intracellular Molecules" that include fixation with paraformaldehyde and permeabilization with saponin .

Published data shows successful detection of TLR7 in RPMI8226 human myeloma cell line and Ramos human Burkitt's lymphoma cell line using this methodology .

What are the recommended protocols for using TLR7 antibodies in assessing cellular activation?

To assess cellular activation using TLR7 antibodies:

• NK cell activation: Coat wells of a 96-well flat-bottom plate with 20 μg/mL of antibody in PBS. Add freshly isolated NK cells at 2×10^5 cells/well with CD107a-FITC or isotype control. Incubate for 4 hours at 37°C, then harvest cells and stain with CD56-PE for FACS analysis of CD107a surface expression .

• Monocyte stimulation: Stimulate monocytes for 18 hours with immobilized antibodies, then collect cells and extract total RNA using TRIzol. Perform Real-Time PCR for activation markers such as TNF-α using pre-designed TaqMan® Gene Expression Assays .

• Phospho-signaling: To assess TLR7-mediated signaling, analyze phosphorylation events by western blotting using antibodies against phospho-ERK1/2 (Thr202/Tyr204) and pan phosphor-tyrosine .

• Cytokine production: Measure cytokines released upon TLR7 stimulation as markers of activation using ELISA or other cytokine detection methods.

How can researchers effectively measure TLR7-mediated B cell responses?

To effectively measure TLR7-mediated B cell responses:

• Germinal center formation: Assess percentages of germinal center B cells by flow cytometry using markers like GL7, CD95, and PNA in combination with B cell markers (CD19, B220) after TLR7 stimulation .

• Plasma cell differentiation: Measure plasma cell frequencies (CD138+ cells) by flow cytometry as done in studies with NZBWF1 mice .

• Antibody production: Quantify antibody secretion (particularly IgG subclasses like IgG2b/2c) by ELISA, as TLR7 signaling promotes isotype switching .

• BCR repertoire analysis: For advanced analysis, perform deep sequencing of the BCR repertoire of antigen-specific B cells to assess diversity, as TLR7 signaling has been shown to drive BCR repertoire development and maintain clonal diversity .

• Affinity/avidity maturation: Evaluate antibody affinity maturation through techniques like surface plasmon resonance or ELISA with chaotropic agents, as TLR7 signaling enhances affinity/avidity maturation of antibodies .

How does TLR7 expression and function differ across immune cell populations?

TLR7 expression and function vary significantly across immune cell types:

• B cells: Express functional TLR7 that directly influences B cell activation, germinal center formation, and antibody production. TLR7 signaling in B cells is critical for BCR repertoire development and diversity .

• Plasmacytoid dendritic cells (pDCs): High expression of TLR7, which upon activation leads to type I interferon production. Functionally impaired pDCs have been linked to human autoimmunity .

• Monocytes: Different monocyte subsets express varying levels of TLR7. In lupus models, Ly6C-low patrolling monocytes expressed high levels of TLR7 and upregulated lupus-associated IL-10, CD115, CD31, and TNFSF15 .

• Conventional dendritic cells (cDCs): Express TLR7 but at lower levels than pDCs. Anti-TLR7 antibody treatment can inhibit TLR7 responses in DCs .

• T cells: Do not directly express high levels of TLR7, but their activation can be indirectly affected by TLR7 signaling in antigen-presenting cells. Anti-TLR7 mAb treatment decreased CD4+ memory T cells, likely through effects on dendritic cells .

What strategies can be employed to study TLR7 function specifically in B cells?

To study TLR7 function specifically in B cells:

• Chimeric mouse models: Create chimeric mice lacking TLR7 expression exclusively in B cells, as described in studies showing that enhanced IgG responses were driven by a B cell intrinsic mechanism .

• B cell isolation and in vitro stimulation: Isolate primary B cells and stimulate with TLR7 agonists like ssRNA or synthetic compounds (imiquimod, resiquimod) to assess activation markers, proliferation, and antibody production.

• Flow cytometric analysis: Analyze B cell subsets (naïve, memory, germinal center, plasma cells) by flow cytometry to assess the effects of TLR7 stimulation or blockade on B cell differentiation .

• BCR sequencing: Perform deep sequencing of the BCR repertoire of antigen-specific B cells to assess how TLR7 signaling affects antibody diversity and hypermutation .

• Ex vivo analysis: Compare B cells from TLR7-deficient and wild-type mice, or from mice treated with anti-TLR7 antibodies versus control antibodies, to understand TLR7's role in B cell function .

How does TLR7 contribute to monocyte function in health and disease?

TLR7 plays important roles in monocyte function:

In health:

• Mediates recognition of viral ssRNA, contributing to antiviral immunity

• Regulates monocyte activation and cytokine production

• Influences monocyte differentiation and polarization

In disease (particularly lupus):

• Monocyte subsets: TLR7 drives lupus-associated increases in Ly6C-low patrolling monocytes in circulation, spleen, and glomeruli .

• Cytokine production: Patrolling monocytes with high TLR7 expression upregulate lupus-associated IL-10, CD115, CD31, and TNFSF15 .

• Tissue infiltration: In NZBWF1 lupus mice, patrolling monocytes infiltrate glomeruli, expressing high levels of FcγRIV and TREML4. Anti-TLR7 mAb treatment reduced this infiltration .

• Organ damage: TLR7-dependent monocytosis contributes to kidney damage in lupus nephritis, with approximately 40% of glomeruli containing CD11b+ cells in elderly NZBWF1 mice compared to <10% in healthy controls .

• Therapeutic target: Anti-TLR7 mAb abolished lupus-associated increases in patrolling monocytes, suggesting TLR7 as a therapeutic target for monocyte-mediated pathologies in SLE .

How effective are anti-TLR7 antibodies in lupus nephritis models?

Anti-TLR7 antibodies have shown significant efficacy in lupus nephritis models:

• Proteinuria reduction: Anti-TLR7 mAb treatment reduced proteinuria in NZBWF1 mice, a well-established model of lupus nephritis .

• Autoantibody inhibition: The treatment decreased serum levels of autoantibodies and IgG deposition in glomeruli by inhibiting TLR7-dependent activation and differentiation of autoreactive B cells .

• Cellular changes: Anti-TLR7 mAb decreased the frequencies of germinal center B cells, plasma cells, and CD4+ memory T cells in NZBWF1 mice .

• Splenomegaly reduction: The antibody abolished splenomegaly in NZBWF1 mice, reducing spleen weight and splenocyte numbers .

• Monocyte normalization: Anti-TLR7 mAb treatment reduced lupus-associated increases in patrolling monocytes in the circulation, spleen, and glomeruli .

• Glomerular protection: The treatment decreased the number of glomeruli containing CD11b+ cells from approximately 40% in untreated NZBWF1 mice to levels closer to healthy controls (<10%) .

These results suggest that TLR7 is a promising therapeutic target for SLE, with anti-TLR7 mAb potentially targeting both B cells and monocytes/macrophages in the disease pathway .

What mechanisms underlie TLR7's role in autoimmune pathology?

Several mechanisms underlie TLR7's role in autoimmune pathology:

• B cell hyperactivation: TLR7 promotes autoreactive B cell activation, differentiation into plasma cells, and autoantibody production .

• Loss of B cell tolerance: TLR7 signaling may bypass normal B cell tolerance mechanisms by providing strong activation signals to autoreactive B cells.

• Monocyte dysregulation: TLR7 drives expansion of patrolling monocytes that express high levels of TLR7 and upregulate lupus-associated factors like IL-10, CD115, CD31, and TNFSF15 .

• Tissue infiltration: TLR7-dependent monocytes infiltrate target tissues like glomeruli, expressing markers FcγRIV and TREML4, contributing to organ damage .

• Interferon pathway activation: TLR7 stimulation in plasmacytoid dendritic cells leads to type I interferon production, a hallmark of many autoimmune diseases, particularly SLE.

• T cell modulation: TLR7 signaling indirectly affects CD4+ T cell responses, with anti-TLR7 mAb treatment reducing CD4+ memory T cells in lupus models .

How can TLR7 antibodies be used to elucidate disease mechanisms beyond lupus?

TLR7 antibodies can elucidate disease mechanisms beyond lupus in several ways:

• Viral immunity: Use anti-TLR7 antibodies to study the role of TLR7 in recognizing viral ssRNA and mounting antiviral responses, potentially relevant to viral pathogenesis and vaccine development.

• Cancer immunology: Investigate TLR7's role in cancer immunity, as TLR7 signaling can enhance antigen presentation and T cell responses. Anti-TLR7 antibodies can help determine if TLR7 activation promotes or inhibits tumor growth in different cancer models.

• Allergic diseases: Study TLR7's contribution to allergic inflammation, as demonstrated by research showing TLR7-dependent effects on allergen-specific antibody responses (e.g., to cat allergen Fel d 1) .

• Vaccine development: Use TLR7 antibodies to understand how TLR7 signaling shapes antibody responses to vaccines, particularly those using virus-like particles (VLPs) that naturally package ssRNA .

• Neurodegenerative diseases: Explore TLR7's role in neuroinflammation, as TLR7 is expressed in brain tissues and may contribute to inflammatory processes in neurodegenerative diseases.

• COVID-19 research: Investigate TLR7's role in SARS-CoV-2 recognition and immune responses, potentially identifying how TLR7 contributes to protective immunity or pathological inflammation.

What are common technical challenges when working with TLR7 antibodies and how can they be addressed?

Common technical challenges with TLR7 antibodies include:

• Intracellular staining difficulties:

  • Challenge: TLR7 is primarily intracellular, making detection challenging

  • Solution: Use proper fixation and permeabilization protocols. For example, fix cells with Flow Cytometry Fixation Buffer and permeabilize with Flow Cytometry Permeabilization/Wash Buffer I .

• Background staining:

  • Challenge: Non-specific binding causing high background

  • Solution: Use appropriate blocking agents, include isotype controls (e.g., MAB003 for TLR7 antibody MAB5875) , and optimize antibody concentration.

• Low signal intensity:

  • Challenge: Weak detection of TLR7

  • Solution: Use signal amplification methods, optimize antibody concentration, ensure cells express detectable levels of TLR7, and consider using cell lines known to express TLR7 (e.g., RPMI8226, Ramos) .

• Antibody storage and handling:

  • Challenge: Loss of antibody activity

  • Solution: Store antibodies according to manufacturer recommendations. For example, store at -20 to -70°C for 12 months as supplied, at 2 to 8°C for 1 month after reconstitution, or at -20 to -70°C for 6 months after reconstitution .

• Epitope masking during fixation:

  • Challenge: Fixation may mask the epitope recognized by the antibody

  • Solution: Try different fixation methods or use live cell staining for surface epitopes.

How can researchers integrate TLR7 antibody data with other experimental approaches for comprehensive pathway analysis?

To integrate TLR7 antibody data with other approaches:

• Multi-omics integration:

  • Combine TLR7 antibody-based flow cytometry data with transcriptomics (RNA-seq) to correlate TLR7 protein expression with gene expression profiles

  • Integrate proteomics data to understand how TLR7 signaling affects the broader cellular proteome

• Signaling pathway analysis:

  • Use phospho-specific antibodies to detect downstream signaling molecules activated by TLR7 (e.g., phospho-ERK1/2)

  • Combine with inhibitor studies to map the TLR7 signaling cascade

• Genetic approaches:

  • Complement antibody studies with CRISPR-Cas9 TLR7 knockout models

  • Use TLR7 chimeric mice (e.g., mice lacking TLR7 only in B cells) to understand cell-specific effects

• Functional assays:

  • Combine TLR7 detection with functional readouts such as cytokine production, cell activation markers, or antibody secretion

  • Use ADCC assays to understand effector functions

• Spatial analysis:

  • Integrate flow cytometry data with immunohistochemistry to understand TLR7 distribution in tissues

  • Use multiplexed imaging to correlate TLR7 with other markers in situ

What cutting-edge applications are emerging for TLR7 antibodies in immunological research?

Emerging cutting-edge applications for TLR7 antibodies include:

• Single-cell analysis:

  • Using TLR7 antibodies in single-cell proteomics to understand cellular heterogeneity in TLR7 expression and signaling

  • Combining with single-cell RNA-seq to correlate TLR7 protein levels with transcriptional profiles

• Therapeutic antibody development:

  • Developing function-blocking anti-TLR7 antibodies as potential therapeutics for autoimmune diseases like SLE

  • Engineering antibodies with improved specificity, half-life, or tissue penetration

• Targeted drug delivery:

  • Using TLR7 antibodies to deliver drugs or siRNAs specifically to TLR7-expressing cells

  • Developing antibody-drug conjugates targeting TLR7-high pathogenic cells

• B cell repertoire engineering:

  • Utilizing understanding of TLR7's role in shaping BCR repertoire diversity to engineer desired antibody responses

  • Combining TLR7 modulation with vaccination approaches

• Immune monitoring:

  • Developing TLR7 antibody-based assays for monitoring disease activity or treatment response in autoimmune conditions

  • Creating multiplexed panels including TLR7 and related signaling molecules

• Organoid and 3D culture systems:

  • Applying TLR7 antibodies to study receptor distribution and function in complex 3D immune cell cultures or organ-on-chip models

  • Investigating TLR7 biology in physiologically relevant tissue contexts

These advancing applications highlight the continued importance of TLR7 antibodies as versatile tools in immunological research, from basic science to translational applications.